News
NKTR
37.27
+0.05%
0.02
How Investors Are Reacting To Nektar Therapeutics (NKTR) Phase 3 Trial Starts
Simply Wall St · 23h ago
Nektar Therapeutics Earnings Call Signals Clinical Momentum
TipRanks · 1d ago
Nektar Therapeutics (NKTR) Has Investors Asking A Bigger Question
Simply Wall St · 2d ago
Nektar (NKTR) Q3 2026 Earnings Call Transcript
The Motley Fool · 2d ago
Nektar price target lowered to $40 from $50 at Wedbush
TipRanks · 2d ago
Piper Sandler Keeps Their Buy Rating on Nektar Therapeutics (NKTR)
TipRanks · 2d ago
Oppenheimer Remains a Buy on Nektar Therapeutics (NKTR)
TipRanks · 2d ago
Nektar Therapeutics Q3 EPS $(1.63) Beats $(2.08) Estimate, Sales $9.386M Miss $10.274M Estimate. Cash and Investments $952.9M
Benzinga · 3d ago
Press Release: Nektar Therapeutics Announces Third Quarter 2026 Financial Results
Dow Jones · 3d ago
*Nektar Therapeutics 3Q Loss $55.7M >NKTR
Dow Jones · 3d ago
Nektar Therapeutics Announces Third Quarter 2026 Financial Results
PR Newswire · 3d ago
*Nektar Therapeutics 3Q Rev $9.39M >NKTR
Dow Jones · 3d ago
*Nektar Therapeutics 3Q Loss/Shr $1.63 >NKTR
Dow Jones · 3d ago
Press Release: Nektar Therapeutics Announces -2-
Dow Jones · 3d ago
Here are the major earnings after the close Thursday
Seeking Alpha · 3d ago
Nektar Therapeutics to Participate in Two Investor Conferences in November
PR Newswire · 4d ago
Weekly Report: what happened at NKTR last week (1102-1106)?
Weekly Report · 11/09 09:35
Earnings Week Ahead: CSCO, CRWV, PLUG, ALC, AMAT, ACB, RKLB, ASTS, and more
Seeking Alpha · 11/08 13:07
What Nektar Therapeutics Stock's Late Stage Eczema Drug Progress Means For Shareholders
Simply Wall St · 11/08 09:35
Nektar Therapeutics (NKTR) Draws Fresh Eczema Buzz Following A 72% Undervalued Narrative
Simply Wall St · 11/07 08:40
More
Webull provides a variety of real-time NKTR stock news. You can receive the latest news about Nektar Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About NKTR
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.